Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University

Abstract

Background. The increasing incidence of primary cutaneous B-cell lymphomas (PCBCLs) presents new challenges for clinicians. Despite advances in the clinical and pathologic characterization of PCBCL, the significance of the current staging approach as a risk profiling tool and the effect of various treatments on outcome remain unclear. Materials and Methods. We retrospectively reviewed patients who presented with a diagnosis of PCBCL seen at The Ohio State University between 1998 and 2012. We reviewed the initial presentation and treatment modality.We then assessed whether the treatment modality (conservative skin-directed vs. definitive radiation with or without systemic therapy), stage (T1 or $T2), or histologic subtype (primary cutaneous follicle center lymphoma [PCFCL] vs. primary cutaneous marginal zone B-cell lymphoma [PCMZL]) affected the riskof recurrence. Results. We identified 67 patients referred with an initial diagnosis of PCBCL. After imaging, 12 did not meet the criteria

AL amyloidosis with a localized B cell neoplasia

“…Considering the clinical presentation, most of the herein analyzed cases presented as localized processes, in which a sparse local clonal plasmacytic infiltration causes a localized amyloid deposition within the tissue in an otherwise healthy patient without overt lymphoma. The final classification as a localized disease is solely possible ruling out a secondary infiltration by an underlying systemic plasmacytic-differentiated B cell lymphoma by appropriate staging as proposed for comparable entities like primary cutaneous lymphomas [21][22][23].…”

Intralesional rituximab in the treatment of indolent primary cutaneous B‐cell lymphoma

“…Dear Editor , Primary cutaneous B‐cell lymphomas (PCBCLs) are a heterogeneous group of extranodal lymphomas 1 . Primary cutaneous marginal zone lymphoma (MZL) and follicle centre lymphoma (FCL), the most prevalent PCBCLs, are typically indolent.…”

“…Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas DOI: 10.1111/bjd.19495 DEAR EDITOR, Primary cutaneous anaplastic lymphomas (pcALCLs) commonly present as solitary or grouped skin lesions and have a 5-year specific survival greater than 91%. [1][2][3] One study showed that, in cases of extracutaneous extension, 5-year overall survival (OS) is 41%. 4 At diagnosis some patients have skin and locoregional node involvement, but their prognosis is as favourable as that of patients with lesions limited to the skin.…”

“…4 At diagnosis some patients have skin and locoregional node involvement, but their prognosis is as favourable as that of patients with lesions limited to the skin. 1 Optimal treatment for these patients (brentuximab vedotin, multiagent chemotherapies or less intensive therapies such as methotrexate or radiation) is currently unknown. [5][6][7] The aim of our study was to assess the prognosis of patients with pcALCL and regional lymph node involvement at diagnosis according to different treatment regimens.…”

Experience in application of the confocal laser scanning microscopy of the skin is diagnosis of primary cutaneous diffuse large B-cell lymphoma

“…Первичные лимфомы кожи (ПЛК) представляют собой гетерогенную группу заболеваний, развитие которых обусловлено неопластической пролиферацией в коже клонов Т-лимфоцитов, NK-клеток или В-лимфоцитов, аффинных к кожной ткани. По данным литературы [1][2][3], заболеваемость первичными кожными лимфомами в мире варьирует от 0,3 до 1,18 случаев на 100 тыс. населения и продолжает увеличиваться.…”